GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr

GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022

CCI approves acquisition of corporate restructuring of GlaxoSmithKline Consumer Healthcare

The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger

GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22

EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.

Study shows Glaxo-Vir drug works against Omicron mutations

Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19

GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr

GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021

GlaxoSmithKline delivers 19% revenue growth for Q1 FY22

The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited

GlaxoSmithKline approves sale of Vemgal plant

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS

GlaxoSmithKline Pharmaceuticals Q3FY21 consolidated PAT at Rs. 156.51 Cr

The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.

GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal

Alembic receives FDA final approval for Sumatriptan Injection USP

Sumatriptan injection is indicated in adults for the acute treatment of migraine